| http://www.w3.org/ns/prov#value | - Tarceva is currently approved in markets including Europe and the U.S. as first-line maintenance therapy for NSCLC patients and as a second-line treatment for advanced or metastatic NSCLC, irrespective of EGFR mutation status. ?? 2013 Genetic Engineering & Biotechnology News, All Rights Reserved
|
